The style of research that we are talking about here is different from clinical studies such as drug trials. Participants are not asked to take part in a medical experiment. They are asked to allow researchers to use their data -genetic, non-genetic and medical -in order to feed a huge data resource that then will be managed by bioinformaticians and used by scientists. It can be exploited for many research purposes like good university libraries or archives can also be exploited for many different research purposes. The ethical issues are less the potential risks involved in the experiment but the confidentiality of data, which, since the genome is personal, can never be anonymised irreversibly and be perfectly safe. People, in principle, could always be tracked down, if somebody is not daunted by the effort that it needs. However, perhaps the confidentiality issue is not the key issue here, because only some information may prove sensitive for the research participants. Quite to the contrary, the disclosure rather than the containment may be the much more tricky issue to solve by good biobank governance i.e., the handling of health related "additional" and "incidental" findings. How much information feedback is fair to the participants and how should communication in both ways be organised? The two basic ethical questions that are raised here are these: (1) Do researchers have a moral duty to tell the participant in case they find predictive genomic information that could be used by the participant to prevent a disease? If there should be such a duty, it is still to be decided whether it outweighs the patient's right not to know and how the patient can exert her or his right not to know without knowing its content. (2) Does the participant have a moral duty to know health related predictive genomic information that could be used to prevent a disease? If there should be such a duty, we need to clarify under which conditions it exists and on which ethical base it rests. What is at stake here is the communication regime around biobanks. We need to understand the normative contents of and the values involved in the relationship between the researchers and the participants of biobanks. They might not be the same as in imaging studies, where, for instance, in a computed tomography scan of the brain a tumour could be discovered. This tumour then needs immediate treatment, it is a definite disease but the patient is in fact unaware of it, whereas the gene variants are not diseases, not even undiscovered germs for diseases. They are variants that might lead to a disease in the future -with a certain probability. The communication regime; therefore, also includes questions of participation. How much should the participants be able to shape the terms and conditions of disclosure, i.e., the rules of genetic transparency [3] with regard to their own lives? Additionally, how can they make their own 'good' decisions about which kind of information they want to have disclosed and which kind they want to ignore? In systems medicine, therefore, large groups of people are becoming involved in this new type of research. Regular patients all become genomic patients. While 'free and informed consent' was the key for organising clinical studies ethically, here, new and appropriate modes of recognising the participants as subjects, i.e., new ways of participation and partnership with the participants need to be found. Informed consent will still be important, but as a stand-alone principle it is insufficient. The questions to be answered first appear on a meta level, where the terms and conditions of this genomic information partnership are negotiated. Several models are possible, ranging from no disclosure of research grade information, partial disclosure on demand, mandatory partial disclosure, complete disclosure on demand, finally to participants' open access to raw data [4] . -I hope for a broad and open debate to clarify which one is best in particular types of cases and in a particular society. That decision cannot be taken just from the therapeutic ethos of "doctor knows best". Funding / potential competing interests: No potential conflicts of interest reported.
